6-Diazo-5-oxo-L-nor-Leucine

6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity^[1][2][3]. IC50 & Target:Bacterial^[3]. In Vitro:6-Diazo-5-oxo-L-nor-Leucine (DON) (0.3 mM; 1 h) shows inhibition of glutamine catabolism in WI-L2 cells^[1].
6-Diazo-5-oxo-L-nor-Leucine (DON) decreases the selfrenewal potential and metastatic ability of tumor cell^[2]. In Vivo:6-Diazo-5-oxo-L-nor-Leucine sensitizes pancreatic tumors to anti-PD1 resulting in tumor regression and prolonged survival in vivo^[2].
6-Diazo-5-oxo-L-nor-Leucine decreases hyaluronan and collagen in the tumor microenvironment, leading to an extensive remodeling of the ECM (extensive extracellular matrix), and an increases infiltration CD8⁺ T-cells^[2].